Comparing Outcome of Thoracocentesis and Pigtail Catheter Drainage in Treatment of Patients With Hepatic Hydrothorax
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- percentage of empyema in patients with hepatic hydrothorax after thoracocentesis
研究概览
简要总结
Hepatic hydrothorax (HH) is a pleural effusion that develops in a patient with cirrhosis and portal hypertension in the absence of cardiopulmonary disease (Lv et al., 2018). Several factors are known to contribute to the development of effusion; the most accepted mechanism of which is the direct delivery of ascitic fluid from the peritoneal cavity to the pleural cavity by "positive" intra-abdominal pressure and a "negative" intrathoracic pressure of the pleural cavity through microscopic congenital diaphragmatic defects (Han et al., 2022).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients who met the following inclusion criteria were enrolled:
- •Liver cirrhosis (with or without hepatocellular carcinoma).
- •Hepatic hydrothorax (bilateral or unilateral).
排除标准
- •patients with a pleural effusion due to a condition other than HH.
- •who had a diagnosis of tuberculosis pleurisy, parapneumonic effusion, inflammatory pleuritis, other neoplasms, and congestive heart failure.
研究组 & 干预措施
hepatic hydrothorax
patient with hepatic hydrothorax that develop pleural effusion either unilateral or bilateral
干预措施: Thoracocentasis (Procedure)
结局指标
主要结局
percentage of empyema in patients with hepatic hydrothorax after thoracocentesis
时间窗: 12 months
Patients with hepatic hydrothorax that undergo repeated thoracocentesis will be monitored for presence of any side effects as empyema
次要结局
未报告次要终点
研究者
Aya Ashraf Abdelkareem
Resident of Tropical medicine and gastroenterology department, Sohag University Hospitals
Sohag University